More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the launch of ResQ215B, a Phase 2 ...

More than 30 million people with HIV must take antiretroviral therapy (ART) medications daily to keep the virus under control, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS). The ...

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor ...

Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration ...

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Higher CD4⁺ T-cell recovery correlated with more rapid neutrophil engraftment Accelerated NK-cell recovery: Natural killer ...

GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31 ...

Recent press releases from two new partners of NextGenNK highlight important advances in natural killer (NK) cell-based immunotherapies, spanning both ...

A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to ...

SynGenSys, a biotechnology company designing synthetic gene promoter systems to address critical bottlenecks in biopharma manufacturing and enhance cell and gene therapy development, today announced ...

Live-action adaptations of animated series can be a double-edged sword; they often face scrutiny from fans who hold the original material dear. However, the adaptation of 'Cells at Work' has managed ...